… machinery. Axiomer® RNA editing technology harnesses ADAR(Adenosine Deaminase Acting on RNA), which is machinery … designing and implementing a new product planning process Leads new product planning, positioning, and pre-launch …
… machinery. Axiomer® RNA editing technology harnesses ADAR(Adenosine Deaminase Acting on RNA), which is machinery … Director (Full-time) to join us for a 9-12 month period to lead the Regulatory Affairs activities to cover maternity …
… machinery. Axiomer® RNA editing technology harnesses ADAR(Adenosine Deaminase Acting on RNA), which is machinery … Leiden, NL (on-site) The Senior Clinical Scientist will lead the scientific and operational elements of the Clinical …
… machinery. Axiomer® RNA editing technology harnesses ADAR(Adenosine Deaminase Acting on RNA), which is machinery … and goals and manage the facilities budget Establish and lead the facility team to ensure the successful establishment …
Preclinical and translational pipeline program data for AX-0810 for Cholestatic Diseases targeting NTCP and AX-1412 for Cardiovascular Disease targeting B4GALT1 anticipated in 2024, building further momentum toward the clinicAccelerated development of Axiomer™ for CNS ap
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1; initiation of clinical trials anticipated in late 2024/early 2025
Axiomer activity demonstrated across multiple preclinical in vitro
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1
Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas
Stre